PhaseBio Pharmaceuticals, Inc. Banner Image

PhaseBio Pharmaceuticals, Inc.

  • Ticker PHAS
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
PhaseBio Pharmaceuticals, Inc. Logo Image
  • 11-50 Employees
  • Based in Malvern, Pennsylvania
PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular and cardiopulmonary diseases. The company’s pipeline includes: bentracimab, a novel reversal agent for the antiplatelet therapy ticagrelor; PB1046, a once-weekly vasoactive intestinal peptide receptor agonist for the treatmentMore of pulmonary arterial hypertension and hospitalized COVID-19 patients at high risk for rapid clinical deterioration and acute respiratory distress syndrome; and PB6440, an oral agent for the treatment of resistant hypertension. PhaseBio’s proprietary elastin-like polypeptide technology platform enables the development of therapies with potential for less-frequent dosing and improved pharmacokinetics, including PB1046, and drives both internal and partnership drug-development opportunities.
4.8 / 5.0 (172)

PhaseBio Pharmaceuticals, Inc. reports have an aggregate usefulness score of 4.8 based on 172 reviews.

PhaseBio Pharmaceuticals, Inc.

Most Recent Annual Report

PhaseBio Pharmaceuticals, Inc.
MOST RECENT 2021 Annual Report and Form 10K

Older/Archived Annual Reports

PhaseBio Pharmaceuticals, Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!